5,6-Dihydro-5-fluorouracil (5-FUH2), the main catabolite of the anticancer drug 5-fluorouracil (5-FU), can be quantitated in human serum simultaneously with the pro-drug 5'-deoxy-5-fluorouridine (5'-dFUR), the parent drug 5-FU and the anabolites 5-fluorouridine and 2'-deoxy-5-fluorouridine by gradient elution-reversed phase liquid chromatography coupled to diode array UV detection. The analytes were extracted (after protein precipitation with ammonium sulphate) with ethyl acetate-isopropanol (90:10, v/v). The average recovery for 5-FUH2 was 78.0% at 0.5 microg/ml level. 5-FUH2 response was linear over three concentration decades and its detection limit was 200 ng/ml of serum. The analytical procedure has been used for simultaneous monitoring of 5'-dFUR, 5-FU and 5-FUH2 levels in the serum of a patient under 5'-dFUR chemotherapy.
Simultaneous determination of 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5,6-dihydro-5-fluorouracil in serum by liquid chromatography with diode array UV detection
GUERRIERI, Antonio;
1994-01-01
Abstract
5,6-Dihydro-5-fluorouracil (5-FUH2), the main catabolite of the anticancer drug 5-fluorouracil (5-FU), can be quantitated in human serum simultaneously with the pro-drug 5'-deoxy-5-fluorouridine (5'-dFUR), the parent drug 5-FU and the anabolites 5-fluorouridine and 2'-deoxy-5-fluorouridine by gradient elution-reversed phase liquid chromatography coupled to diode array UV detection. The analytes were extracted (after protein precipitation with ammonium sulphate) with ethyl acetate-isopropanol (90:10, v/v). The average recovery for 5-FUH2 was 78.0% at 0.5 microg/ml level. 5-FUH2 response was linear over three concentration decades and its detection limit was 200 ng/ml of serum. The analytical procedure has been used for simultaneous monitoring of 5'-dFUR, 5-FU and 5-FUH2 levels in the serum of a patient under 5'-dFUR chemotherapy.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
